HK1244685A1 - 液體藥物組合物 - Google Patents
液體藥物組合物Info
- Publication number
- HK1244685A1 HK1244685A1 HK18104147.4A HK18104147A HK1244685A1 HK 1244685 A1 HK1244685 A1 HK 1244685A1 HK 18104147 A HK18104147 A HK 18104147A HK 1244685 A1 HK1244685 A1 HK 1244685A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pharmaceutical composition
- liquid pharmaceutical
- liquid
- composition
- pharmaceutical
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14199871 | 2014-12-22 | ||
PCT/EP2015/080326 WO2016102328A1 (en) | 2014-12-22 | 2015-12-17 | Liquid pharmaceutical composition |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1244685A1 true HK1244685A1 (zh) | 2018-08-17 |
Family
ID=52134031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18104147.4A HK1244685A1 (zh) | 2014-12-22 | 2018-03-26 | 液體藥物組合物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10959939B2 (zh) |
EP (1) | EP3236990B1 (zh) |
JP (1) | JP6885875B2 (zh) |
CN (1) | CN107205925B (zh) |
AU (2) | AU2015371381A1 (zh) |
BR (1) | BR112017013269A2 (zh) |
CA (1) | CA2970577A1 (zh) |
ES (1) | ES2833506T3 (zh) |
HK (1) | HK1244685A1 (zh) |
IL (1) | IL252871B (zh) |
WO (1) | WO2016102328A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006259664A1 (en) | 2005-06-14 | 2006-12-28 | Amgen Inc. | Self-buffering protein formulations |
CN114917185B (zh) * | 2016-10-21 | 2023-11-14 | 美国安进公司 | 药物配制品及其制备方法 |
US11253569B2 (en) | 2018-05-03 | 2022-02-22 | Seattle Children's Hospital | Methods of treating Kawasaki Disease |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
CA2485553A1 (en) | 1989-09-05 | 1991-03-21 | Immunex Corporation | Tumor necrosis factor - .alpha. and - .beta. receptors |
KR100232688B1 (ko) | 1992-09-15 | 1999-12-01 | 스코트 쥐. 홀퀴스트 | 종양 괴사 인자 길항제를 함유하는 tnf-의존성 염증 치료용 제약 조성물 |
DE60322513D1 (de) | 2002-02-27 | 2008-09-11 | Immunex Corp | Stabilisierte TNFR-Fc Formulierung mit Arginin |
AU2004262014B2 (en) | 2003-08-01 | 2010-06-17 | Amgen Inc. | Crystalline tumor necrosis factor receptor 2 polypeptides |
RU2600847C2 (ru) | 2010-05-10 | 2016-10-27 | Интас Биофармасьютикалс Лимитед | Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина |
ES2759931T3 (es) * | 2011-04-20 | 2020-05-12 | Sandoz Ag | Formulaciones líquidas farmacéuticas estables de la proteína de fusión TNFR:Fc |
TR201903445T4 (tr) | 2011-06-01 | 2019-03-21 | Green Cross Corp | Sglt2 i̇nhi̇bi̇törleri̇ olarak yeni̇ di̇feni̇lmetan türevleri̇ |
UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
CN103930124B (zh) | 2011-07-01 | 2021-05-11 | 生物基因Ma公司 | 无精氨酸的tnfr:fc-融合多肽组合物及使用方法 |
PT2768525T (pt) * | 2011-10-18 | 2019-07-17 | Coherus Biosciences Inc | Formulações etanercept estabilizadas com iões de magnésio |
EP2919812A4 (en) * | 2012-11-19 | 2016-05-18 | Merck Sharp & Dohme | Liquid formulations for TNFR: FC fusion proteins |
JP2014214153A (ja) * | 2013-04-30 | 2014-11-17 | ニプロ株式会社 | 水溶液製剤およびその製造方法 |
KR101712245B1 (ko) * | 2013-11-29 | 2017-03-06 | 아레스 트레이딩 에스.에이. | TNFR 및 면역글로블린 Fc 영역을 포함하는 융합 단백질을 포함하는 액상 제제 |
-
2015
- 2015-12-17 CA CA2970577A patent/CA2970577A1/en active Pending
- 2015-12-17 BR BR112017013269-9A patent/BR112017013269A2/pt not_active IP Right Cessation
- 2015-12-17 EP EP15813418.9A patent/EP3236990B1/en active Active
- 2015-12-17 CN CN201580072898.6A patent/CN107205925B/zh active Active
- 2015-12-17 US US15/536,941 patent/US10959939B2/en active Active
- 2015-12-17 AU AU2015371381A patent/AU2015371381A1/en not_active Abandoned
- 2015-12-17 ES ES15813418T patent/ES2833506T3/es active Active
- 2015-12-17 JP JP2017550999A patent/JP6885875B2/ja active Active
- 2015-12-17 WO PCT/EP2015/080326 patent/WO2016102328A1/en active Application Filing
-
2017
- 2017-06-13 IL IL252871A patent/IL252871B/en active IP Right Grant
-
2018
- 2018-03-26 HK HK18104147.4A patent/HK1244685A1/zh unknown
-
2021
- 2021-10-15 AU AU2021250949A patent/AU2021250949A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US10959939B2 (en) | 2021-03-30 |
US20170348225A1 (en) | 2017-12-07 |
WO2016102328A1 (en) | 2016-06-30 |
ES2833506T3 (es) | 2021-06-15 |
EP3236990B1 (en) | 2020-09-02 |
JP6885875B2 (ja) | 2021-06-16 |
CN107205925A (zh) | 2017-09-26 |
EP3236990A1 (en) | 2017-11-01 |
CA2970577A1 (en) | 2016-06-30 |
CN107205925B (zh) | 2020-12-11 |
JP2018501311A (ja) | 2018-01-18 |
AU2021250949A1 (en) | 2021-11-11 |
IL252871A0 (en) | 2017-08-31 |
IL252871B (en) | 2021-01-31 |
AU2015371381A1 (en) | 2017-07-20 |
BR112017013269A2 (pt) | 2018-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL282481A (en) | A liquid pharmaceutical preparation | |
ZA201901590B (en) | Liquid pharmaceutical composition | |
IL277241A (en) | A liquid pharmaceutical preparation | |
ZA201901736B (en) | Liquid pharmaceutical composition | |
HK1257026A1 (zh) | 液體藥物組合物 | |
SG11201605366QA (en) | Pharmaceutical composition containing pyridylaminoacetic acidcompound | |
AU2014386903B2 (en) | Liquid pharmaceutical composition | |
LT3206666T (lt) | Skysta farmacinė kompozicija, apimanti pemetreksedą | |
HK1244685A1 (zh) | 液體藥物組合物 | |
IL253572A0 (en) | A liquid pharmaceutical preparation |